A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PHILOGEN operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 80M | 80M | 25M |
| Net Income | 49M | 49M | -6.7M |
| EPS | $1.21 | $1.21 | $-0.16 |
| Free Cash Flow | 42M | 42M | -11M |
| ROIC | 39.2% | 28.9% | -8.7% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.09 | 0.02 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | 41M | 41M | -9.6M |
| Operating Margin | 51.0% | 51.0% | -38.2% |
| ROE | 32.7% | 39.4% | -6.8% |
| Shares Outstanding | 40M | 40M | 41M |
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Income Statement | |||
| Revenue | 25M | 80M | 80M |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -9.6M | 41M | 41M |
| Op. Margin | -38.2% | 51.0% | 51.0% |
| Net Income | -6.7M | 49M | 49M |
| Net Margin | -26.6% | 61.2% | 61.2% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -8.7% | 28.9% | 39.2% |
| ROE | -6.8% | 39.4% | 32.7% |
| ROA | -5.2% | 31.4% | 26.9% |
| Cash Flow | |||
| Op. Cash Flow | -5.2M | 44M | 44M |
| Free Cash Flow | -11M | 42M | 42M |
| Owner Earnings | -5.7M | 41M | 41M |
| CapEx | 6.0M | 2.3M | 2.3M |
| Maint. CapEx | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | 2.3M |
| D&A | 0 | 0 | 0 |
| CapEx/OCF | N/A | 5.3% | 5.3% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 2.6M | 29K | 29K |
| Buyback Yield | 0.3% | 0.0% | 0.0% |
| Stock-Based Comp | 428K | 3.1M | 3.1M |
| Debt Repayment | 888K | 3.0M | 3.0M |
| Balance Sheet | |||
| Net Debt | -15M | -19M | -33M |
| Cash & Equiv. | 17M | 33M | 33M |
| Long-Term Debt | 2.1M | N/A | N/A |
| Debt/Equity | 0.02 | 0.09 | 0.00 |
| Interest Coverage | -3.6 | 11.5 | 11.5 |
| Equity | 98M | 150M | 150M |
| Total Assets | 129M | 182M | 182M |
| Total Liabilities | 31M | 32M | 32M |
| Intangibles | 1.4M | 1.3M | 1.3M |
| Retained Earnings | N/A | N/A | N/A |
| Working Capital | 83M | 125M | 125M |
| Current Assets | 97M | 143M | 143M |
| Current Liabilities | 14M | 18M | 18M |
| Per Share Data | |||
| EPS | -0.16 | 1.21 | 1.21 |
| Owner EPS | -0.14 | 1.01 | 1.01 |
| Book Value | 2.39 | 3.70 | 3.70 |
| Cash Flow/Share | -0.13 | 1.09 | 1.21 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 41.1M | 40.4M | 40.4M |
| Valuation | |||
| P/E Ratio | -122.9 | 16.4 | 16.4 |
| P/FCF | N/A | 19.2 | 19.2 |
| EV/EBIT | N/A | 19.3 | 18.9 |
| Price/Book | 8.4 | 5.4 | 5.4 |
| Price/Sales | 32.7 | 10.1 | 10.0 |
| FCF Yield | -1.4% | 5.2% | 5.2% |
| Market Cap | 822M | 804M | 803M |
| Avg. Price | 17.55 | 20.77 | 19.86 |
| Year-End Price | 20.01 | 19.88 | 19.86 |
PHILOGEN passes 3 of 9 quality checks, indicating weak fundamentals.
PHILOGEN trades at 16.4x trailing earnings, compared to its 15-year median P/E of 16.4x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 19.2x vs a median of 19.2x. The company's 5-year average ROIC is 10.1%. At current prices, the estimated annualized return to fair value is +103.0%.
PHILOGEN (PHIL-MI) has a current P/E ratio of 16.4, compared to its historical median P/E of 16.4. The stock is currently considered Cheap based on its historical valuation range.
PHILOGEN (PHIL-MI) has a 5-year average return on invested capital (ROIC) of 10.1%. This indicates solid capital allocation.
PHILOGEN (PHIL-MI) has a market capitalization of $803M. It is classified as a small-cap stock.
PHILOGEN (PHIL-MI) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.00%.
Based on historical P/E analysis, PHILOGEN (PHIL-MI) appears cheap. The current P/E of 16.4 is 0% below its historical median of 16.4. The estimated fair value CAGR (P/E method) is 84.0%.
PHILOGEN (PHIL-MI) operates in the Biotechnology industry, within the Healthcare sector.
PHILOGEN (PHIL-MI) reported annual revenue of $80 million in its most recent fiscal year, based on SEC EDGAR filings.
PHILOGEN (PHIL-MI) has a net profit margin of 61.2%. This is a strong margin indicating high profitability.
PHILOGEN (PHIL-MI) generated $42 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
PHILOGEN (PHIL-MI) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
PHILOGEN (PHIL-MI) reported earnings per share (EPS) of $1.21 in its most recent fiscal year.
PHILOGEN (PHIL-MI) has a return on equity (ROE) of 39.4%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 2 years of financial data for PHILOGEN (PHIL-MI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PHILOGEN (PHIL-MI) has a book value per share of $3.70, based on its most recent annual SEC filing.
No recent items.